IPSC today
$1.64+$0.01 (+0.61%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourBearish
1 hourSymmetric Triangle
15 minBullish
5 minStrong Bearish
Daily trend turns up above $3.04
Key levels
Resistance$2.15
Resistance$1.90
Support$1.55
Support$1.37
Latest news & SEC filings
EarningsCentury Therapeutics Posts Q3 2026 Results, Business Update
SEC FilingCentury Therapeutics, Inc. filed a report on a major company event (Form 8-K)
EarningsCentury Therapeutics posts narrower Q3 loss of $0.11 per share
All IPSC news →About Century Therapeutics
Century Therapeutics is a biotechnology company that makes off-the-shelf cell treatments grown from reprogrammed stem cells. Its programs include pancreatic islet cells for type 1 diabetes, engineered T cells for autoimmune conditions driven by B cells, and natural killer cells under study in autoimmune disease. The company uses gene editing and immune-cloaking modifications so its products can be given to patients without matching donors or long-term immune suppression.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Century Therapeutics, Inc. (IPSC)
What Is the Price Target for IPSC?
SEPT Low Target
$5.00
SEPT Mid Target
$8.00
SEPT High Target
$8.00
Analyst Consensus
$8.00
Is IPSC a Buy or Sell Right Now?
Thesis
- •Revenue growing 1556.8% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IPSC.
Start Free Trial →Is IPSC Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$6.73
25
Moat Score
NONE
4/9
Piotroski Score
-2.8
Altman Z-Score
What Is Smart Money Doing with IPSC?
Insider Signal
SELLING
0 buys / 10 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Carr Douglas | officer | Sale | 266 | $404.05 | Nov 3, 2026 |
| Russotti Gregory | officer | Sale | 2,584 | $6K | Jun 12, 2026 |
| Carr Douglas | officer | Sale | 1,654 | $4K | Jun 12, 2026 |
| Cowan Chad | officer | Sale | 358 | $801.92 | Jun 11, 2026 |
| Pfeiffenberger Brent | director officer | Sale | 13,849 | $31K | Jun 11, 2026 |
| Russotti Gregory | officer | Sale | 524 | $1K | Jun 8, 2026 |
| Carr Douglas | officer | Sale | 249 | $525.64 | Jun 8, 2026 |
| Pfeiffenberger Brent | director officer | Sale | 463 | $986.19 | Jun 5, 2026 |
| Pfeiffenberger Brent | director officer | Sale | 31,172 | $73K | May 15, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →IPSC Growth Story
Revenue YoY
1556.8%
3yr Revenue CAGR
175.9%
EPS Growth YoY
91.3%
FCF Growth YoY
5.0%
Revenue Trend
ACCELERATING
Dark Pool Trades for IPSC
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for IPSC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:31:59 | $1.63 | 1,170 | $$2K | SELL |
| 18:01:21 | $1.63 | 1,800 | $$3K | MIDPOINT |
| 18:01:21 | $1.63 | 1,800 | $$3K | BUY |
| 17:27:33 | $1.63 | 2,840 | $$5K | SELL |
| 15:32:07 | $1.56 | 4,900 | $$8K | SELL |
5 dark pool trades shown · $$20K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Century Therapeutics, Inc. (IPSC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IPSC — frequently asked questions
What is IPSC stock price today?
Century Therapeutics, Inc. (IPSC) is at $1.64, up 0.61% (+$0.01) at the Nov 13, 2026 close.
Why is IPSC stock moving today?
Latest IPSC news — Nov 12, 2026: Century Therapeutics Posts Q3 2026 Results, Business Update · Nov 12, 2026: Century Therapeutics, Inc. filed a report on a major company event (Form 8-K)
What is the IPSC price target?
The average analyst price target for IPSC is $8.00, ranging from $5 to $8, based on 3 analysts. Latest: Mizuho initiates on May 27, 2026.
What do analysts rate IPSC?
Analyst ratings for IPSC: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did IPSC beat earnings?
IPSC last reported on Aug 12, 2026: EPS -$0.17 vs -$0.11 expected — a miss of 54.5%.
Does IPSC pay a dividend?
IPSC does not currently pay a dividend.
What are IPSC support and resistance levels?
Support: $1.55, $1.37, $0.54. Resistance: $1.90, $2.15, $2.36.
What are insiders doing with IPSC?
Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.
What is the latest news on IPSC?
Nov 12, 2026: Century Therapeutics Posts Q3 2026 Results, Business Update · Nov 12, 2026: Century Therapeutics, Inc. filed a report on a major company event (Form 8-K) · Nov 12, 2026: Century Therapeutics posts narrower Q3 loss of $0.11 per share